Kiwi Wealth Investments Limited Partnership increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 72,842 shares of the biopharmaceutical company’s stock after purchasing an additional 3,869 shares during the quarter. Kiwi Wealth Investments Limited Partnership’s holdings in Gilead Sciences were worth $4,556,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Athena Capital Advisors LLC bought a new stake in Gilead Sciences during the fourth quarter valued at $27,000. Advisors Preferred LLC bought a new stake in Gilead Sciences during the fourth quarter worth about $31,000. Legacy Financial Advisors Inc. lifted its stake in Gilead Sciences by 361.3% during the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 383 shares during the last quarter. We Are One Seven LLC bought a new stake in Gilead Sciences during the fourth quarter worth about $37,000. Finally, Larson Financial Group LLC bought a new stake in Gilead Sciences during the fourth quarter worth about $38,000. Institutional investors own 80.13% of the company’s stock.

In other news, Director Gayle E. Wilson sold 19,068 shares of Gilead Sciences stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the transaction, the director now owns 143,567 shares in the company, valued at $9,630,474.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total value of $175,689.00. Following the completion of the transaction, the director now owns 57,560 shares in the company, valued at approximately $3,745,429.20. The disclosure for this sale can be found here. 1.16% of the stock is currently owned by insiders.

Several brokerages have issued reports on GILD. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. Mizuho reaffirmed a “buy” rating and set a $88.00 price target on shares of Gilead Sciences in a research note on Tuesday, February 26th. Citigroup reaffirmed a “buy” rating and set a $100.00 price target on shares of Gilead Sciences in a research note on Tuesday, February 5th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Thursday, March 7th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Hold” and an average price target of $82.29.

GILD opened at $63.77 on Monday. The stock has a market capitalization of $81.34 billion, a PE ratio of 10.37, a P/E/G ratio of 4.01 and a beta of 1.16. The company has a current ratio of 3.38, a quick ratio of 3.30 and a debt-to-equity ratio of 1.19. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.78 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $2.52 annualized dividend and a dividend yield of 3.95%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s payout ratio is currently 40.98%.

COPYRIGHT VIOLATION NOTICE: “Kiwi Wealth Investments Limited Partnership Buys 3,869 Shares of Gilead Sciences, Inc. (GILD)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2019/03/25/kiwi-wealth-investments-limited-partnership-buys-3869-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Read More: Bear Market – How and Why They Occur

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.